^
BIOMARKER:
HER-2 amplification
i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
Related biomarkers:
›
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HER-2 amplification
|
Breast Cancer
|
HER-2 amplification
|
Breast Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HER-2 amplification
|
CRC
|
HER-2 amplification
|
CRC
|
trastuzumab + pertuzumab Sensitive: A2 - Guideline
|
trastuzumab + pertuzumab Sensitive: A2 - Guideline
|
HER-2 amplification
|
CRC
|
HER-2 amplification
|
CRC
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
HER-2 amplification
|
CRC
|
HER-2 amplification
|
CRC
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
|
HER-2 amplification
|
Rectal Cancer
|
HER-2 amplification
|
Rectal Cancer
|
trastuzumab + pertuzumab Sensitive: A2 - Guideline
|
trastuzumab + pertuzumab Sensitive: A2 - Guideline
|
HER-2 amplification
|
Rectal Cancer
|
HER-2 amplification
|
Rectal Cancer
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
|
HER-2 amplification
|
Rectal Cancer
|
HER-2 amplification
|
Rectal Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
HER-2 amplification
|
Gastric Cancer
|
HER-2 amplification
|
Gastric Cancer
|
trastuzumab Sensitive: B - Late Trials
|
trastuzumab Sensitive: B - Late Trials
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
trastuzumab Sensitive: B - Late Trials
|
trastuzumab Sensitive: B - Late Trials
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab Sensitive: B - Late Trials
|
trastuzumab Sensitive: B - Late Trials
|
HER-2 amplification
|
Gastric Cancer
|
HER-2 amplification
|
Gastric Cancer
|
lapatinib Sensitive: B - Late Trials
|
lapatinib Sensitive: B - Late Trials
|
HER-2 amplification
|
GastroEsophageal Cancer
|
HER-2 amplification
|
GastroEsophageal Cancer
|
trastuzumab Sensitive: B - Late Trials
|
trastuzumab Sensitive: B - Late Trials
|
HER-2 amplification
|
Breast Cancer
|
HER-2 amplification
|
Breast Cancer
|
neratinib Sensitive: C1 - Off-label
|
neratinib Sensitive: C1 - Off-label
|
HER-2 amplification
|
Breast Cancer
|
HER-2 amplification
|
Breast Cancer
|
lapatinib Sensitive: C2 – Inclusion Criteria
|
lapatinib Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Breast Cancer
|
HER-2 amplification
|
Breast Cancer
|
tucatinib Sensitive: C2 – Inclusion Criteria
|
tucatinib Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab + trastuzumab Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Gastric Cancer
|
HER-2 amplification
|
Gastric Cancer
|
pembrolizumab + trastuzumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab + trastuzumab Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
NSCLC
|
HER-2 amplification
|
NSCLC
|
afatinib Sensitive: C2 – Inclusion Criteria
|
afatinib Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Urothelial Cancer
|
HER-2 amplification
|
Urothelial Cancer
|
afatinib Sensitive: C2 – Inclusion Criteria
|
afatinib Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Solid Tumor
|
HER-2 amplification
|
Solid Tumor
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Gastric Cancer
|
HER-2 amplification
|
Gastric Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Esophageal Cancer
|
HER-2 amplification
|
Esophageal Cancer
|
ibrutinib Sensitive: C2 – Inclusion Criteria
|
ibrutinib Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Breast Cancer
|
HER-2 amplification
|
Breast Cancer
|
eFT226 Sensitive: C2 – Inclusion Criteria
|
eFT226 Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Breast Cancer
|
HER-2 amplification
|
Breast Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
NSCLC
|
HER-2 amplification
|
NSCLC
|
dacomitinib Resistant: C2 – Inclusion Criteria
|
dacomitinib Resistant: C2 – Inclusion Criteria
|
HER-2 amplification
|
Salivary Gland Cancer
|
HER-2 amplification
|
Salivary Gland Cancer
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Gastric Cancer
|
HER-2 amplification
|
Gastric Cancer
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Esophageal Cancer
|
HER-2 amplification
|
Esophageal Cancer
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HM 78136B Sensitive: C2 – Inclusion Criteria
|
HM 78136B Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Endometrial Cancer
|
HER-2 amplification
|
Endometrial Cancer
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Lung Cancer
|
HER-2 amplification
|
Lung Cancer
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Gastric Cancer
|
HER-2 amplification
|
Gastric Cancer
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Esophageal Adenocarcinoma
|
HER-2 amplification
|
Esophageal Adenocarcinoma
|
trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Gastric Adenocarcinoma
|
HER-2 amplification
|
Gastric Adenocarcinoma
|
trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Salivary Gland Cancer
|
HER-2 amplification
|
Salivary Gland Cancer
|
trastuzumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Solid Tumor
|
HER-2 amplification
|
Solid Tumor
|
SBT6050 Sensitive: C2 – Inclusion Criteria
|
SBT6050 Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
NSCLC
|
HER-2 amplification
|
NSCLC
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
NSCLC
|
HER-2 amplification
|
NSCLC
|
rivoceranib + pyrotinib Sensitive: C3 – Early Trials
|
rivoceranib + pyrotinib Sensitive: C3 – Early Trials
|
HER-2 amplification
|
CRC
|
HER-2 amplification
|
CRC
|
panitumumab Resistant: C3 – Early Trials
|
panitumumab Resistant: C3 – Early Trials
|
HER-2 amplification
|
Gallbladder Cancer
|
HER-2 amplification
|
Gallbladder Cancer
|
trastuzumab Sensitive: C3 – Early Trials
|
trastuzumab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Gallbladder Cancer
|
HER-2 amplification
|
Gallbladder Cancer
|
lapatinib Sensitive: C3 – Early Trials
|
lapatinib Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Gallbladder Cancer
|
HER-2 amplification
|
Gallbladder Cancer
|
trastuzumab + lapatinib Sensitive: C3 – Early Trials
|
trastuzumab + lapatinib Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Cholangiocarcinoma
|
HER-2 amplification
|
Cholangiocarcinoma
|
trastuzumab Sensitive: C3 – Early Trials
|
trastuzumab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
trastuzumab + lapatinib Sensitive: C3 – Early Trials
|
trastuzumab + lapatinib Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Solid Tumor
|
HER-2 amplification
|
Solid Tumor
|
KN046 + KN026 Sensitive: C3 – Early Trials
|
KN046 + KN026 Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Bladder Cancer
|
HER-2 amplification
|
Bladder Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Biliary Tract Cancer
|
HER-2 amplification
|
Biliary Tract Cancer
|
pyrotinib Sensitive: C3 – Early Trials
|
pyrotinib Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Urothelial Cancer
|
HER-2 amplification
|
Urothelial Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Gastric Cancer
|
HER-2 amplification
|
Gastric Cancer
|
cabazitaxel Sensitive: C3 – Early Trials
|
cabazitaxel Sensitive: C3 – Early Trials
|
HER-2 amplification
|
NSCLC
|
HER-2 amplification
|
NSCLC
|
gefitinib Resistant: C3 – Early Trials
|
gefitinib Resistant: C3 – Early Trials
|
HER-2 amplification
|
Endometrial Cancer
|
HER-2 amplification
|
Endometrial Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Endometrial Cancer
|
HER-2 amplification
|
Endometrial Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Endometrial Cancer
|
HER-2 amplification
|
Endometrial Cancer
|
pyrotinib Sensitive: C3 – Early Trials
|
pyrotinib Sensitive: C3 – Early Trials
|
HER-2 amplification
|
NSCLC
|
HER-2 amplification
|
NSCLC
|
erlotinib Resistant: C3 – Early Trials
|
erlotinib Resistant: C3 – Early Trials
|
HER-2 amplification
|
Melanoma
|
HER-2 amplification
|
Melanoma
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
NSCLC
|
HER-2 amplification
|
NSCLC
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Salivary Gland Cancer
|
HER-2 amplification
|
Salivary Gland Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Ovarian Cancer
|
HER-2 amplification
|
Ovarian Cancer
|
pyrotinib Sensitive: C3 – Early Trials
|
pyrotinib Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Prostate Cancer
|
HER-2 amplification
|
Prostate Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Ovarian Cancer
|
HER-2 amplification
|
Ovarian Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + margetuximab Sensitive: C3 – Early Trials
|
pembrolizumab + margetuximab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
LUAD
|
HER-2 amplification
|
LUAD
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
HER-2 amplification
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine + neratinib Sensitive: C3 – Early Trials
|
ado-trastuzumab emtansine + neratinib Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Gastric Cancer
|
HER-2 amplification
|
Gastric Cancer
|
pembrolizumab + margetuximab Sensitive: C3 – Early Trials
|
pembrolizumab + margetuximab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Pancreatic Cancer
|
HER-2 amplification
|
Pancreatic Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Salivary Gland Cancer
|
HER-2 amplification
|
Salivary Gland Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Salivary Gland Cancer
|
HER-2 amplification
|
Salivary Gland Cancer
|
pyrotinib Sensitive: C3 – Early Trials
|
pyrotinib Sensitive: C3 – Early Trials
|
HER-2 amplification
|
CRC
|
HER-2 amplification
|
CRC
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
HER-2 amplification
|
Ovarian Cancer
|
HER-2 amplification
|
Ovarian Cancer
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Uterine Cancer
|
HER-2 amplification
|
Uterine Cancer
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Biliary Tract Cancer
|
HER-2 amplification
|
Biliary Tract Cancer
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Cholangiocarcinoma
|
HER-2 amplification
|
Cholangiocarcinoma
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Gastric Adenocarcinoma
|
HER-2 amplification
|
Gastric Adenocarcinoma
|
HER2 inhibitor Resistant: C3 – Early Trials
|
HER2 inhibitor Resistant: C3 – Early Trials
|
HER-2 amplification
|
Uterine Cancer
|
HER-2 amplification
|
Uterine Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Solid Tumor
|
HER-2 amplification
|
Solid Tumor
|
pembrolizumab + SBT6050 Sensitive: C3 – Early Trials
|
pembrolizumab + SBT6050 Sensitive: C3 – Early Trials
|
HER-2 amplification
|
LUAD
|
HER-2 amplification
|
LUAD
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|
